Aurore Morello

Head of Research, Director of R&D Program OSE Immunotherapeutics

Aurore Morello holds a PhD in Immunology and bispecific targeted immunotherapy for cancer treatment and transplantation (Immunoconcept Bordeaux France),
After her PhD, she performed a post doc at the Memorial Sloan Kettering Cancer center (MSKCC, New York) in the laboratory of Dr Adusumilli (thoracic surgery department). She worked on development of CAR T cell therapy & combination with immune checkpoint blockade or cell intrinsic strategies for the treatment of solid tumors. Since 2016, She joined OSE Immunotherapeutics French biotech company as Scientist & project became head of research, Director of R&D programs for the development of first in class immunotherapeutic approaches in immuno-oncology and immuno-inflammation using antibodies, immunocytokines and mRNA therapeutic approaches to modulate immune system.

Seminars

Thursday 11th December 2025
Novel Agonist Anti-GPCR Antibody to Trigger Resolution of Inflammation
2:15 pm
  • First-in-class antibody targeting GPCR with agonistic activity
  • Anti-GPCR antibody to trigger resolution of inflammation and treat chronic inflammatory diseases
  • Agonist Antibodies inhibit inflammatory immune cell recruitment and activation
Aurore Morello